Full Press Release Details
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting.
ARGX
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
Key Takeaway: argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis